Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Recent studies from University of Montreal add new data to HIV/AIDS
April 23rd, 2008
According to recent research published in the Journal of Experimental Medicine, "The world of human immunodeficiency virus (HIV) vaccines has suffered a baffling setback. The first trial of a vaccine designed to elicit strong cellular immunity has shown no protection against infection." "More alarmingly, the vaccine appeared to increase the rate of HIV infection in individuals with prior immunity against the adenovirus vector used in the vaccine. A new study in this issue suggests that a different vaccine approach-using a DNA prime/poxvirus boost strategy-induces polyfunctional immune responses to an HIV immunogen," wrote R.P. Sekaly and colleagues, University of...
Source: Vaccine Weekly (2008-04-23)
|
